Wire · opportunities
Biosimilars face a slowdown in development
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 September 2026 · Fusion42 review
Biosimilar drug development is slowing despite a wave of biologic patent expirations expected in the next decade, with only 1 in 10 branded biologics having biosimilar alternatives in the pipeline. Legislative efforts and FDA regulatory changes aim to reduce clinical requirements, but market incentives and patent strategies by originator companies are limiting competition and delaying cost savings for patients.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Drugmakers and biosimilar developers face a tougher market as the usual cost-saving pathway narrows due to patent games and slow uptake; you need to engage policymakers on patent reform and prepare for complex market entry. Congressional bills are creating new openings for regulatory shortcuts—move fast to shape these rules or risk missing out.
◆ Coverage
1 source · 15 Sep 2026
◆ Related on Wire
◆ Topics